NEW YORK, Oct. 04, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Endo International plc (NASDAQ:ENDP) between November 30, 2012 and July 6, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Bier v. Endo International plc, et al. (Case No. 2:17-cv-03711-TJS) in the USDC for the Eastern District of Pennsylvania. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra-sbm/endo-international-plc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana ER. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.
If you suffered a loss in Endo you have until October 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
OpenAI Addresses Security Vulnerability in macOS App Certification Process
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Bill Ackman Eyes New Fund to Bet Against Market Complacency 



